Cequence Security Raises $60M in Series C Funding to Meet Surging Demand for its Innovative API Security Platform
15.12.2021 17:00:00 EET | Business Wire | Press release
Cequence Security, the leader in API security, today announced it has closed $60 million in Series C funding led by new investor Menlo Ventures. Additional participation comes from new investors ICON Ventures, Telstra Ventures and HarbourVest Partners. Existing investors Shasta Ventures, Dell Technologies Capital and T-Mobile Ventures also participated in this funding round. The latest round of funding brings total investment in the company to $100 million.
This new financing comes on the heels of record growth for Cequence, driven by advancements in business applications in response to the COVID-19 pandemic. Across multiple industries, companies have accelerated their digital transformation projects and deployed a growing number of new APIs, but in the process, they have overlooked traditional security reviews and governance best practices.
Cequence’s API security solution is the most comprehensive platform on the market and its success in protecting 2 billion API transactions per day is unmatched by competitors. Cequence works tirelessly to help organizations protect their APIs and their businesses with API inventory tracking, risk assessment and threat prevention—all performed natively and at runtime.
This hard work has proven fruitful, as Cequence services over 85 brands worldwide, including several Fortune 500 and 100 companies in markets ranging from banking and beauty, to retail and consumer mobile apps.
VP Analyst at Gartner, Mark O’Neill and Jeremy D'Hoinne, emphasizes in 2021 Gartner® “Hype Cycle™ for Application Security, 2021” report.
“Many organizations lack visibility of their APIs, as many APIs are used as part of web or mobile applications and not published directly. This means that a key requirement of API threat protection is API discovery, since, as every security professional knows, you can’t secure what you don’t know.” 1
“As an active cybersecurity investor, I’ve looked at countless API security vendors, but I’m placing my bets on Cequence—as is the market. Among their impressive roster of customers, you’ll find several household names and Fortune 500 organizations, which speaks to their ability to meet the API protection demands of the largest and most demanding enterprise businesses,” said Venky Ganesan, partner at Menlo Ventures. “Part of the appeal is superior product architecture. Cequence can stand alone: It is the only solution that provides visibility and inline response mitigation to attacks on APIs. It’s the only solution out there that doesn’t need to signal other products for mitigation.”
The funding will support new enhancements to Cequence’s API security solutions and the expansion of its product offerings. It will also help the company break into new regions in the United States and Europe, as well as new markets in Asia and Australia. In turn, Cequence will be looking to aggressively hire and grow its team within these geographies. As part of the transaction, Venky Ganesan of Menlo Ventures will also join the company’s board.
“From social networks to online shopping and financial services, so many aspects of our lives and digital experiences are tied to APIs. That’s why it’s critical to be able to manage your entire API inventory to address security gaps and protect against rising API threats that may lead to fraud and data loss,” said Larry Link, CEO of Cequence Security. “We’re thrilled that our new and existing investors recognize this growing market need and are eager to support our mission to protect organizations—and users—in this digital-first world.”
To learn more about Cequence’s API visibility and protection capabilities or to schedule a demo, visit: https://www.cequence.ai/
1 Gartner, “Hype Cycle™ for Application Security, 2021, Joerg Fritsch, 12 July 2021.
Gartner Disclaimer:
GARTNER and HYPE CYCLE are a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission.
About Cequence Security
Organizations trust Cequence Security to protect their APIs and web applications with the most effective and adaptive defense against online fraud, business logic attacks, exploits and unintended data leakage; which enables them to remain resilient in today’s ever-changing business and threat landscape. Cequence is the only API Security Platform offering that unifies API discovery, inventory tracking, risk analysis and remediation with proven, real-time threat protection against ever evolving online attacks. Learn more at www.cequence.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005012/en/
Contact information
Merritt Group for Cequence Security
Ashley Long
cequence@merrittgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
